Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 13Rectal Neoplasms 4Neoplasm Metastasis 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Advanced Solid Tumors 2Stomach Neoplasms 1Solid Tumor Cancer 1Sarcoma, Ewing 1Sarcoma 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Microsatellite-stable Colorectal Cancer 1Metastatic Gastric Adenocarcinoma 1Lung Neoplasms 1HER2 IHC3+ Advanced Colorectal Cancer 1Endometrial Neoplasms 1Desmoid Tumors 1Craniopharyngioma 1Colorectal Cancer Metastatic 1Breast Neoplasms 1Anal Cancer Metastatic 1Advanced Microsatellite Stable Colorectal Cancer 1Adenomatous Polyposis Coli 1

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Gastric Adenocarcinoma × trifluridine tipiracil drug combination × 90 days × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡